Similarities in the stimulus-secretion coupling mechanisms of glucose- and 2-keto acid-induced insulin release.
The stimulus-secretion coupling of 2-keto acid-induced insulin release was investigated using 2-ketoisocaproate (4-methyl-2-oxopentanoate) as the principal model secretagogue. 2-Ketoisocaproate and 2-ketocaproate (2-oxo-, hexanoate) provoked changes in B cell electrical behavior characterized by an initial depolarization of the membrane potential, followed by rapid spike activity, which appeared either in a bursting pattern or as continuous activity. The onset of spike activity induced by 2-ketoisocaproate (5 mM) was biphasic in nature. The dynamic pattern of 2-ketoisocaproate-induced insulin release was also biphasic. 2-[U-14C]Ketoisocaproate (10 mM) was oxidized in islet tissue at a rate equivalent to that of [U-14C]glucose (17 mM) and a t a higher rate than 2-ketoisovalerate (3-methyl-2-oxobutyrate) and 2-keto-3-methyl-valerate, which were poor secretagogues. Like glucose, 2-ketoisocaproate provoked characteristic changes in 86Rb and 45Ca efflux from prelabeled islets and stimulated 45Ca net uptake. Proinsulin synthesis was stimulated by 2-ketoisocaproate through both a general effect on protein synthesis and a specific effect on hormonal biosynthesis. 2-Ketoisocaproate and 2-ketocaproate reproduced the effect of glucose on the islet content of ATP, ADP, AMP, NAD+, NADH, NADP+, and NADPH. These findings together with a series of observations on the effects upon the above parameters of site-specific inhibitors, e.g. respiratory inhibitors, suloctidil, theophylline, and epinephrine, suggested that the stimulus-secretion-coupling mechanisms for 2-ketoisocaproate- and glucose-induced release are similar. It is postulated that glucose- and 2-keto acid-induced insulin release may be initiated by a common signal.
D000227:Adenine Nucleotides / Q000378:metabolism; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000502:physiology*; D007651:Keto Acids / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects; D010084:Oxidation-Reduction; D051381:Rats; D012413:Rubidium / Q000378:metabolism; D013329:Structure-Activity Relationship
D000227:Adenine Nucleotides; D007328:Insulin; D007651:Keto Acids; D005947:Glucose; D012413:Rubidium; D002118:Calcium